Analysts See $-0.43 EPS for GTx, Inc. (GTXI)

July 14, 2018 - By Mary Kidd

GTx, Inc. (NASDAQ:GTXI) Logo

Analysts expect GTx, Inc. (NASDAQ:GTXI) to report $-0.43 EPS on August, 13.They anticipate $0.03 EPS change or 7.50 % from last quarter’s $-0.4 EPS. After having $-0.62 EPS previously, GTx, Inc.’s analysts see -30.65 % EPS growth. The stock decreased 1.91% or $0.29 during the last trading session, reaching $14.92. About 46,124 shares traded. GTx, Inc. (NASDAQ:GTXI) has risen 489.32% since July 14, 2017 and is uptrending. It has outperformed by 476.75% the S&P500.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. The company has market cap of $358.55 million. It focuses on the development of selective androgen receptor modulators for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). It currently has negative earnings. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI.

Another recent and important GTx, Inc. (NASDAQ:GTXI) news was published by Businesswire.com which published an article titled: “GTx Added to the Russell 3000® Index” on June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.